University of British Columbia
Application of Saccharomyces cerevisiae to improve pediatric acute lymphoblastic leukemia outcomes
Abstract
dc:descriptionPediatric acute lymphoblastic leukemia (ALL) is the most commonly diagnosed childhood cancer in Canada and continues to need improvements in the care patients receive. Saccharomyces cerevisiae (S. cerevisiae) is a generally nonpathogenic organism that has the potential to affect both stages of leukemia (preleukemia and leukemia) and improve ALL outcomes by acting as a drug delivery vehicle for L-ASNase and/or influence leukemogenesis by inducing early-life, antileukemic immune activity. Mild infectious exposures during infancy and childhood has consistently been shown to influence leukemogenesis. In mice, early-life infections can deplete preleukemic cells and prevent preleukemia developing into leukemia. If preleukemia develops into ALL, children undergo chemotherapy that includes the enzyme L-asparaginase (L-ASNase). ALL cells characteristically stop expressing the enzyme asparagine synthetase (AS) and rely on extracellular sources for L-ASN. L-ASNase depletes extracellular L-ASN, selectively starving ALL cells of L-ASN, and consequently inducing their apoptosis. To evaluate the efficacy of S. cerevisiae to improve L-ASNase therapy, it was first engineered to constitutively express cell-wall associated L-ASNase-II (AEY – asparaginase expressing yeast). The cell-wall association may improve ALL therapy by shielding L-ASNase from immune detection and consequently reducing the cost, toxicity, and immunogenicity of L-ASNase therapy. In vitro, AEY co-cultured with ALL cell lines can deplete L-ASN levels leading to apoptosis and inhibited cell growth in the asparagine synthetase (AS)-negative cell line RS4;11, but not the AS-positive cell lines BV173 and 697. The AEY biomass required to yield a therapeutic L-ASNase dose exceeds the current ethical limitations for further study in vivo. To determine if S. cerevisiae can activate early-life, antileukemic immune activity, S. cerevisiae was injected intraperitoneally into day-6-old Eμ-RET mice and the effect on preleukemic burden was assessed. S. cerevisiae is unable to activate the IL-17A and Natural Killer (NK) cell-dependent immune response that has been shown to deplete preleukemic cells. Additionally, both in vitro and in vivo stimulation of NK cells with IL-17A does not directly lead to their activation. Further investigation into the mechanism leading to the activation of antileukemic NK cells may uncover new immunotherapeutic approaches for ALL.
Degree
thesis:*- Name thesis:degree_name
- Master of Science - MSc
- Level thesis:degree_level
- master's
- Discipline thesis:degree_discipline
- Experimental Medicine
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Gynn, Matthew
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/66685